venous thrombosis
Showing 1 - 25 of 122
Intimate Partner Violence asRisk Factor for Venous
Recruiting
- Venous Thrombosis
- WAST questionnaire
-
Nîmes Cedex 09, FranceCHU de Nîmes - Hôpital Universitaire Carémea
Jun 9, 2023
Epidemiology of Venous Thrombosis and Pulmonary Embolism
Active, not recruiting
- Cardiovascular Diseases
- +2 more
- (no location specified)
Nov 14, 2022
Pulmonary Embolism, Venous Thrombosis Trial in Canada, United States (Enteric Coated Aspirin, Warfarin, Rivaroxaban)
Recruiting
- Pulmonary Embolism
- Venous Thrombosis
- Enteric Coated Aspirin
- +2 more
-
Scottsdale, Arizona
- +30 more
Nov 3, 2022
Venous Thrombosis, Tumors, Anticoagulant Trial in Kyoto (12-month Edoxaban, 3-month Edoxaban)
Active, not recruiting
- Venous Thrombosis
- +2 more
- 12-month Edoxaban
- 3-month Edoxaban
-
Kyoto, JapanDepartment of Cardiovascular Medicine, Kyoto University Graduate
Aug 16, 2022
Venous Thrombosis, Catheter-Related Infections, Catheter Mechanical Failure Rate Trial in Taipei (Subclavian vein approach,
Active, not recruiting
- Venous Thrombosis
- +2 more
- Subclavian vein approach
- internal jugular vein approach
-
Taipei, TaiwanNational Taiwan University Hospital
Aug 15, 2022
Venous Thromboembolism, Venous Thrombosis, Pulmonary Embolism Trial
Not yet recruiting
- Venous Thromboembolism
- +2 more
- (no location specified)
Jun 7, 2022
Venous Thrombosis, Tumors Trial in Minneapolis, Columbus, Milwaukee (Heparin, Low-Molecular-Weight, or direct oral
Completed
- Venous Thrombosis
- Neoplasms
- Heparin, Low-Molecular-Weight, or direct oral anticoagulants
-
Minneapolis, Minnesota
- +2 more
Apr 26, 2022
Cirrhosis, Splenectomy, Venous Thrombosis Trial in Yangzhou (Apixaban 2.5 MG, Dipyridamole 25Mg Tab, subcutaneous Low Molecular
Recruiting
- Cirrhosis
- +3 more
- Apixaban 2.5 MG
- +2 more
-
Yangzhou, Jiangsu, ChinaClinical Medical College, Yangzhou University
Apr 30, 2022
Cirrhosis, Splenectomy; Status, Venous Thrombosis Trial in Yangzhou (Apixaban, Warfarin, Aspirin)
Recruiting
- Cirrhosis
- +3 more
- Apixaban
- +4 more
-
Yangzhou, Jiangsu, ChinaClinical Medical College of Yangzhou University
Mar 19, 2022
Venous Thrombosis, Tumors, Anticoagulants Trial in Kyoto (Long DOAC, Short DOAC)
Recruiting
- Venous Thrombosis
- +2 more
- Long DOAC
- Short DOAC
-
Kyoto, JapanDepartment of Cardiovascular Medicine, Kyoto University Graduate
Mar 29, 2022
Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis
Recruiting
- Liver Cirrhosis
- +4 more
- Somatostatin and its analogs
- Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection
-
Shenyang, Liaoning, ChinaDepartment of Gastroenterology, General Hospital of Shenyang Mil
Mar 17, 2022
Venous Thrombosis Trial in Worldwide (Shortened duration (6 weeks) of anticoagulant therapy, Conventional duration (3 months) of
Completed
- Venous Thrombosis
- Shortened duration (6 weeks) of anticoagulant therapy
- +2 more
-
Birmingham, Alabama
- +62 more
Mar 1, 2022
Venous Thrombosis Trial in Seoul ([18F]GP1 positron emission tomography/computed tomography)
Recruiting
- Venous Thrombosis
- [18F]GP1 positron emission tomography/computed tomography
-
Seoul, Korea, Republic ofAsan Medical Center
Feb 15, 2022
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis Trial in Worldwide (Tranexamic Acid, Placebo (Saline),
Active, not recruiting
- Perioperative Bleeding
- +2 more
- Tranexamic Acid
- +3 more
-
New Haven, Connecticut
- +113 more
Jan 24, 2022
Venous Thrombosis, Pregnancy Trial in Houston (antepartum and postpartum)
Active, not recruiting
- Venous Thrombosis
- Pregnancy
- antepartum and postpartum
-
Houston, TexasBaylor College of Medicine
Dec 7, 2021
Venous Thrombosis Trial in Bethlehem (Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily)
Terminated
- Venous Thrombosis
- Arixtra (Fondaparinox) 2.5 mg SC Daily
- Lovenox 40mg SC Daily
-
Bethlehem, PennsylvaniaLehigh Valley Hospital Muhlenberg
Oct 14, 2021
Potential Adverse Outcomes in Routine Clinical Practice
Completed
- Venous Thrombosis
- +3 more
- Rivaroxaban (Xarelto, Bay59-7939)
- Standard of care
-
Multiple Locations, Germany(unnamed)
Oct 21, 2021
Potential Adverse Outcomes in Routine Clinical Pratice
Completed
- Venous Thrombosis
- +3 more
- Rivaroxoban (Xarelto, Bay59-7939)
- Standard of care
-
Multiple Locations, Netherlands(unnamed)
Sep 22, 2021
Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
Completed
- Acute Coronary Syndrome
- +3 more
- Rivaroxaban (Xarelto, BAY59-7939)
- Standard of care drugs
-
Multiple Locations, SwedenMany Locations
Sep 22, 2021
Potential Adverse Outcomes in Routine Clinical Pratice (UK)
Completed
- Venous Thrombosis
- +3 more
- Rivaroxaban (Xarelto, Bay59-7939)
- +2 more
-
Multiple Locations, United Kingdom(unnamed)
Sep 22, 2021
Venous Thrombosis, Arthroplasty, Replacement, Hip Trial (Neuromuscular electrostimulation (NMES) device, Intermittent pneumatic
Completed
- Venous Thrombosis
- Arthroplasty, Replacement, Hip
- Neuromuscular electrostimulation (NMES) device
- Intermittent pneumatic compression (IPC) device
- (no location specified)
Sep 20, 2021
Venous Thrombosis Trial (MRI examination)
Not yet recruiting
- Venous Thrombosis
- MRI examination
- (no location specified)
Aug 17, 2021
Venous Thrombosis Trial in Aurora (low dose intravenous heparin (LDIVH), Heparin)
Completed
- Venous Thrombosis
- low dose intravenous heparin (LDIVH)
- Heparin
-
Aurora, ColoradoUniversity of Colorado Hospital
Jul 7, 2021
Collection of the Thrombo-VaxCov Cohort
Recruiting
- Covid19
- +4 more
- Retrospective data and biological samples
-
Lille, FranceCHU lille
May 11, 2021